CCR5-specific antibodies with HIV neutralizing activity that recognize a linear dodecapeptide that mimics a conformational epitope in the second extracellular loop of CCR5
Patent 8282926 Issued on October 9, 2012. Estimated Expiration Date: December 28, 2029. Estimated Expiration Date is calculated based on simple USPTO term provisions. It does not account for terminal disclaimers, term adjustments, failure to pay maintenance fees, or other factors which might affect the term of a patent.
The present invention relates, e.g., to an isolated peptide comprising a sequence of contiguous amino acids that is at least about 60% identical (e.g., at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 98% or 100% identical) to the sequence E-W-Q-K-E-G-L-V-T-L-W-L (SEQ ID NO:1), or an active variant of an isolated peptide comprising SEQ ID NO:1. Neutralizing antibodies generated by, or specific for, such peptides are also described, in particular antibodies which are specific for the HIV co-receptor, CCR5, and which inhibit infection of a host cell by HIV. Neutralizing single strand and complete human monoclonal antibodies against CCR5 are described. Methods of using such peptides or antibodies, for inhibiting infection by HIV, are also described.
Surender et al., “Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity,” J of Virology, Jun. 2005, pp. 6791-6800, vol. 79, No. 11.
Konigs et al., Monoclonal Antibody Screening of a Phage-Displayed Random Peptide Library Reveals Mimotopes of Chemokine Receptor CCR5: Implication for the Tertiary Structure of the Receptor and for an N-Terminal Binding Site for HIV-1 gp120, European J of Immunology, Apr. 2000, pp. 1162-1171, vol. 30, No. 4.
Wu Lijun et al., “Interaction of Chemokine Receptor CCR5 with its Ligands: Multiple Domains for HIV-1 gp120 Binding and a Single Domain for Chemokine Binding,” J of Experimental Medicine, 1997, pp. 1373-1381, vol. 186, No. 8.
Olson et al., Differential Inhibition of Human Immunodeficiency Virus Type 1 Fusion, GP 120 Binding, and CC-Chemokine Activity by Monoclonal Antibodies to CCR5, J of Virlology, The American Society for Microbiology, May 1999, pp. 4145-4155, vol. 73, No. 5.
Aarons, E. J., et al., 2001, Adaptation to blockade of human immunodeficiency virus type 1 entry imposed by the anti-CCR5 monoclonal antibody, Virol. 287:382-390 (abstract only).
Jekle, A., et al., 2010, Epitope switching as a novel escape mechanism of HIV to CCR5 monoclonal antibodies, Antimicrob. Agents Chemother. 54(2):734-741.
Biswas, P., et al., 2007, Access denied? The status of co-receptor inhibition to counter HIV entry, Exp. Opin. Pharmacother. 8(7):923-933.
Trkola, A., et al., 2005, Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies, Nat. Med. 11(6):615-622.
Bansal, G. P., 2007, A summary of the workshop on passive immunization using monoclonal antibodies for HIV/AIDS, held at the National Institute of Allergy and Infectious Diseases, Bethesda, Mar. 10, 2006, Biol. 35:367-371.
Chen, C., et al., 1995, Enhancement and destruction of antibody function by somatic mutation: unequal occurrence is controlled by V gene combinatorial associations, EMBO J, 14(12):2784-2794.
Watkins, B. A., et al., 1993, Immune escape by human immunodeficiency virus type 1 from neutralizing antibodies: evidence for multiple pathways, J. Virol. 67(12):7493-7500.
Watkins, B. A., et al., 1996, Resistance of human immunodeficiency virus type 1 to neutralization by natural antisera occurs through single amino acid substitutions that cause changes in antibody binding at multiple sites, J. Virol. 70(12):8431-8437.
Grene, E., et al., 2001, Anti-CCR5 antibodies in sera of HIV-positive individuals, Hum. Immunol. 62(2):143-145.